Gestational Diabetes Mellitus and Cardiometabolic Syndrome in Offspring

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

41 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-08-31

Study Completion Date

2013-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Gestational Diabetes Mellitus (GDM) has long been known as leading to macrosomias, neonatal hypoglycemias and other complications which are treatable and preventable. Nowadays, GDM is recognized as an entity with long-term serious sequels to the mother (GDM is considered a forerunner of type 2 diabetes) and her offspring. Indeed, according to the programming hypothesis, GDM sets the stage for metabolic syndrome, obesity, type 2 diabetes and hypertension. However, these cross-sectional studies failed to control for maternal disease history and genetic background although heredity is a major epidemiology risk factor of type 2 diabetes. Also, studies usually refer to traditional markers such as BMI, blood pressure, lipids profile and oral glucose tolerance test (OGTT); none explored inflammatory biomarkers and adipokines in-depth, despite the possible link between their presence and the development of metabolic and cardiovascular diseases in GDM offsprings.

Exclusion of genetic confounding factors will help establish the role of GDM as an independent marker of cardiometabolic risk in GDM offspring. It is highly relevant to identify GDM as a risk factor for cardiometabolic diseases, given the worldwide obesity epidemic, the alarming prevalence increase of GDM and its serious sequels to both mother and offspring.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Gestational Diabetes Mellitus and Neurodevelopment in Newborns

NCT02779452

Diabetes, Gestational Glucose Metabolism Disorders

COMPLETED

Gestational Diabetes Mellitus and Implications for Cardiovascular Disease Risk

NCT00550979

Gestational Diabetes Mellitus

UNKNOWN

Cardiometabolic Health in First Time Pregnancy

NCT05856318

Cardiometabolic Health Pregnancy Related Diabetes +2 more

RECRUITING

Exploration of the Lipid Metabolism During the Diabetic Pregnancies

NCT00639964

Pregnancy Pregnancy in Diabetes Type 1 Diabetes Mellitus +1 more

COMPLETED NA

Possible Epigenetic Changes in Offspring of Women With Pregestational and Gestational Diabetes

NCT01255384

Gestational Diabetes Pregestational Diabetes IDM (Infant of Diabetic Mothers) +2 more

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gestational Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GDM offspring

Children born from gestational diabetes mellitus pregnancy

No interventions assigned to this group

No-GDM offspring

Children born from a normal pregnancy

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age 4 to 12 years
* Tanner stage \< 2
* to understand French or English

Exclusion Criteria

* Type 1 diabetes
* weight \< 10 kg
* placenta abnormalities
* gestational age \< 34 weeks
* illness affecting growth and metabolism
* taking medications

Minimum Eligible Age

4 Years

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No